Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CryositeASX:CTE 46 EV-to-EBITDA is 17.03 as of Jul. 27, 2026, which is 53% above its 10-year median of 11.11. GuruFocus rates ASX:CTE with a GF Score™ of 46/100 and a GF Value™ of A$0.95 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 117 Medical Diagnostics & Research companies, Cryosite ranks worse than 55.56% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cryosite's enterprise value is A$64.85 Mil.
Cryosite's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.81 Mil. Therefore, Cryosite's EV-to-EBITDA for today is 17.03.
The historical rank and industry rank for Cryosite's EV-to-EBITDA or its related term are showing as below:
ASX:CTE'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -14.24 Med: 11.11 Max: 24.98
Current: 17.03
During the past 13 years, the highest EV-to-EBITDA of Cryosite was 24.98. The lowest was -14.24. And the median was 11.11.
ASX:CTE's EV-to-EBITDA is ranked worse than 55.56% of 117
companies
in the Medical Diagnostics & Research industry
Industry Median: 14.4
vs ASX:CTE: 17.03
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Cryosite (ASX:CTE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cryosite's share price for today is A$1.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryosite's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cryosite's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: EV-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Cryosite's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cryosite's EV-to-EBITDA falls into.
Cryosite's current Enterprise Value is A$64.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cryosite's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$3.81 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a EV-to-EBITDA of 17.03 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cryosite. This is 53% above median its historical median of 11.11. According to the industry distribution chart, Cryosite ranks #65 out of 117 companies in the Medical Diagnostics & Research industry, placing it in the top 55.6%.
Is Cryosite's EV-to-EBITDA too high?
Cryosite's current EV-to-EBITDA of 17.03 is 53% above median its 10-year median of 11.11. The Medical Diagnostics & Research industry median EV-to-EBITDA is 14.40. Cryosite's value of 17.03 is 18.3% above this industry median. Based on the distribution chart, Cryosite ranks #65 out of 117 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Cryosite has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's EV-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #65 out of 117 companies for EV-to-EBITDA. This places Cryosite in the lower half of its industry. The industry median EV-to-EBITDA is 14.40. Cryosite's value of 17.03 is 18.3% above this benchmark. While the company's 10-year median is 11.11 vs. the industry median of 14.40, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 14.40, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current EV-to-EBITDA of 17.03 is 18.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cryosite. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 14.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current EV-to-EBITDA is 17.03, which is 53% above median its own 10-year median of 11.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.95, compared to a current price of A$1.20 — trading 26.3% above its estimated fair value. The current EV-to-EBITDA is 17.03, which is 53% above median its 10-year median of 11.11 and 18.3% above the Medical Diagnostics & Research industry median of 14.40. Cryosite's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current EV-to-EBITDA is 17.03 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.20 is trading 26.3% above its estimated GF Value™ of A$0.95.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
EV-to-EBITDA: 17.03 (53% above median its 10-year median of 11.11)
GF Value™: A$0.95 vs. price of A$1.20 (26.3% above fair value)
Industry Position: 18.3% above the Medical Diagnostics & Research median (#65 of 117)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
46GF Score
Get the complete analysis for ASX:CTE
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
